Seamless Therapeutics

Seamless Therapeutics develops gene-editing therapies by using programmable recombinases to correct genetic causes of disease across multiple indications.

Seamless Therapeutics processes personal data in compliance with EU General Data Protection Regulation (GDPR) when users visit or use its website, seamlesstx.com.

The company lists its managing directors as Dr. Albert Seymour and Dr. Anne-Kristin Heninger.

Eli Lilly partners with Seamless Therapeutics to develop gene-editing therapies for genetic hearing loss using a recombinase-based platform. The collaboration could reach **$1.12 billion**, with Lilly gaining exclusive rights to advance candidate treatments. Seamless’s technology enables precise DNA edits by inserting or replacing gene fragments, addressing an unmet need where no approved pharmacological treatments currently exist.

Jan 2026biopharmatrend.comNews article

Seamless Therapeutics partners with Eli Lilly in a **$1.12 billion** research collaboration to advance hearing-loss treatments. The deal uses Seamless’ **recombinase technology** to create programmable therapies targeting auditory disorders. Both companies combine expertise to accelerate drug development in an unmet medical need.

Jan 2026pharmexec.comNews article

Eli Lilly partners with Seamless Therapeutics to develop a gene-editing treatment targeting hearing loss. The collaboration includes an $1.1 billion investment to advance genetic medicine therapies. Seamless Therapeutics specializes in gene-editing approaches for unmet medical needs.

Jan 2026Fierce BiotechNews article

Seamless Therapeutics secures **$25 million in seed funding** to develop **programmable recombinases** for large-scale, precise gene edits targeting unmet medical needs. The company expands operations to the **U.S.** to accelerate its gene-editing platform, addressing diseases with limited treatment options.

Apr 2024Global GenesNews article